{
    "nctId": "NCT04639271",
    "briefTitle": "Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain Metastasis",
    "officialTitle": "A Single-arm, Open-label Study Of Pyrotinib Combined WithTrastuzumab And Abraxane in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, HER2-positive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Objective Response Rate (ORR) of Intracranial Lesion",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \\>18 years.\n* ECOG performance status \u22642.\n* Histologically or cytologic confirmed HER2 positive advanced breast cancer.\n* MRI confirmed brain metastases. According to RECIST 1.1, at least one measurable lesion exists.\n* No limit of previous chemotherapy lines.\n* Previously have not reveived capecitabine or disease progression of capecitabine after 6 months, or progression of capecitabine adjuvant therapy after one year;\n* Life expectancy of more than 3 months.\n* Required laboratory values including following parameters: ANC: \u2265 1.5 x 10\\^9/L;Platelet count: \u2265 100 x 10\\^9/L;Hemoglobin: \u2265 9.0 g/dL;Total bilirubin: \u2264 1.5 x upper limit of normal (ULN);ALT and AST: \u2264 1.5 x ULN (or \u2264 5\u00d7ULN in patients with liver metastases);BUN and creatine clearance rate: \u2265 50 mL/min;LVEF: \u2265 50%;QTcF: \\< 470 ms for female and \\< 450 ms for male.\n* Signed the informed consent form prior to patient entry.\n\nExclusion Criteria:\n\n* Patients with brain metastases who have extensive meningeal metastases and are treated with hormone dehydration.\n* Subjects with third space fluid(such as a large amount of pleural effusion and ascites) that can not be controled by drainage or other methods. (such as pleural effusion and ascites).\n* Received whole brain radiotherapy, chemotherapy, surgery or target therapy within 2 weeks prior to randomization. Received hormone therapy within 1 weeks prior to randomization, Received the nitrosoureas or mitomycin chemotherapy within 6 weeks prior to randomization.\n* Participated in other clinical trial within 4 weeks prior to randomization.\n* Treated or treating with HER2 tyrosine kinase inhibitors (TKIs) (including Lapatinib, Neratinib and Pyrotinib).\n* Second malignancies within 5 years, except for cured carcinoma in-situ of uterine cervix, skin basal cell carcinomaand squamous-cell carcinoma.\n* Receiving any other anti-tumor therapies at time of study screening visit.\n* There are no other serious and/or uncontrolled diseases that may affect research participation, including any of the following: (1) unable to swallow, chronic diarrhea and intestinal obstruction and factors influencing the usage of oral administration; (2) has allergies or a known history of hypersensitivity to the drug components of this program; History of Immunodeficiency, acquired or congenital immunodeficiency (HIV positive) ,history of organ transplantation; (3) History of any kind of Heart disease, including 1) Myocardial infarction; 2) Heart failure; 3) Any other heart disease judged by researcher as not suitable for participating in this study, etc; (4) Infection.\n* All female patients in breastfeeding period or in child-bearing period or with positive pregnancy test result or refusing to take a reliable method of birth control during the study.\n* Any other situations judged by investigator as not suitable for participating in this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}